This is supported by the upregulation of pro-apoptotic genes and proteins such as caspase-3, caspase-9, Bax, and cytochrome C. Further studies need to be conducted to assess the bioavailability potential of DK1 in vivo to confirm its efficacy as an anti-colon carcinoma drug. This evidence concerns the gene BAX and colon carcinoma.